Home Thomson StreetEvents

Nektar Therapeutics Corporate Call for Analysts and Investors to Outline New Strategic Plan Summary

Published Apr 25, 2022

Price US$ 54.00 | Buy this Report Now

About This Report

Abstract:

Edited Brief of NKTR.OQ conference call or presentation 25-Apr-22 9:00pm GMT

Report Type:

Brief

Source:

Thomson StreetEvents

Company:

Nektar Therapeutics

Ticker

NKTR.OQ

Time

9:00pm GMT

Format:

PDF

The following is excerpted from the question-and-answer section of the transcript. (Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session) Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : The main question I have is, would you look to enter into other partnerships similar to the Lilly partnership where you had maybe less upfront investment in a larger company running and paying for the bulk of the pivotal trial? It seems like it might be an efficient way to develop given the need to preserve cash. And then are any of the milestones due from Lilly assumed to be received when -- in your projected cash runway?

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : The main question I have is, would you look to enter into other partnerships similar to the Lilly partnership where you had maybe less upfront investment in a larger company running and paying for the bulk of the pivotal trial? It seems like it might be an efficient way to develop given the need to preserve cash. And then are any of the milestones due from Lilly assumed to be received when -- in your projected cash runway?

Nektar Therapeutics at JPMorgan Healthcare Conference Transcript – 2023-01-11 – US$ 54.00 – Edited Transcript of NKTR.OQ presentation 11-Jan-23 4:15pm GMT

Nektar Therapeutics To Host Investor & Analyst Event Transcript – 2022-12-12 – US$ 54.00 – Edited Transcript of NKTR.OQ corporate analyst meeting</ 12-Dec-22 1:30pm GMT

Nektar Therapeutics Q3 2022 Earnings Call Transcript – 2022-11-03 – US$ 54.00 – Edited Transcript of NKTR.OQ earnings conference call or presentation 3-Nov-22 9:00pm GMT

Nektar Therapeutics Q2 2022 Earnings Call Transcript – 2022-08-04 – US$ 54.00 – Edited Transcript of NKTR.OQ earnings conference call or presentation 4-Aug-22 9:00pm GMT

Nektar Therapeutics Corporate Call for Analysts and Investors to Outline New Strategic Plan Transcript – 2022-04-25 – US$ 54.00 – Edited Transcript of NKTR.OQ conference call or presentation 25-Apr-22 9:00pm GMT

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial Summary – 2022-03-14 – US$ 54.00 – Edited Brief of NKTR.OQ conference call or presentation 14-Mar-22 12:00pm GMT

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial Transcript – 2022-03-14 – US$ 54.00 – Edited Transcript of NKTR.OQ conference call or presentation 14-Mar-22 12:00pm GMT

Nektar Therapeutics Q4 2021 Earnings Call Summary – 2022-02-28 – US$ 54.00 – Edited Brief of NKTR.OQ earnings conference call or presentation 28-Feb-22 10:00pm GMT

Nektar Therapeutics Q4 2021 Earnings Call Transcript – 2022-02-28 – US$ 54.00 – Edited Transcript of NKTR.OQ earnings conference call or presentation 28-Feb-22 10:00pm GMT

Nektar Therapeutics at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-11 – US$ 54.00 – Edited Transcript of NKTR.OQ presentation 11-Jan-22 8:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author

Cite this Report


MLA:	Thomson StreetEvents. "Nektar Therapeutics Corporate Call for Analysts and Investors to Outline New Strategic Plan Summary" Apr 25, 2022. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Nektar-Therapeutics-Corporate-Call-for-Analysts-and-Investors-to-Outline-New-Strategic-Plan-B15187147>

APA:	Thomson StreetEvents. (2022). Nektar Therapeutics Corporate Call for Analysts and Investors to Outline New Strategic Plan Summary Apr 25, 2022. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Nektar-Therapeutics-Corporate-Call-for-Analysts-and-Investors-to-Outline-New-Strategic-Plan-B15187147>

US$ 54.00

$ £ €

Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

Example Report

Click to View Sample Report

More Research

Search all our Credit Research from one place.

Nektar Therapeutics Corporate Call for Analysts and Investors to Outline New Strategic Plan Summary

About This Report

Table Of Contents

More from Thomson StreetEvents

About the Author

Cite this Report